Studies using anti‐PD‐L1 antibodies in patients with metastatic and previously untreated NSCLC are ongoing with preliminary results showing favorable response and acceptable toxicity profile 54, 55 (Table 1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.